{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:57:38Z","timestamp":1781632658293,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK133076"],"award-info":[{"award-number":["R01DK133076"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32 DK101003"],"award-info":[{"award-number":["T32 DK101003"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR063157"],"award-info":[{"award-number":["R01AR063157"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Humans with type 1 diabetes (T1D) have a higher-than-expected fracture risk, and bone is weak in mouse models of T1D. Since hyperglycemia is thought to deleteriously affect tissue-level sensitivity of insulin action, we hypothesized that glucose-lowering by canagliflozin (Cana) improves the ability of insulin treatment to rescue the T1D-related decrease in bone strength. To test this hypothesis, male DBA\/2 mice with and without streptozotocin (STZ)-induced hyperglycemia at 8\u00a0weeks of age were fed a diet with and without Cana (50\u00a0ppm) at 10\u00a0weeks of age and then the T1D mice, regardless of placebo diet or Cana diet, were treated at 14\u00a0weeks of age with a subcutaneous implant (Palm) that does or does not elute insulin. Non-diabetic (ND) mice and T1D mice were euthanized at 22\u00a0weeks of age following weekly measurements of body mass and non-fasting blood glucose. Cana pre-treatment significantly lowered circulating glucose, but not to non-diabetic levels. It did not affect the ability of insulin therapy to reduce glucose. However, pre-treatment significantly affected serum markers of bone resorption (CTX) and bone formation in ways that favored lower CTX across the 3 glucose groups (ND-Palm, T1D-Palm, and T1D-Insulin) and P1NP levels in T1D-Insulin mice that were consistent with P1NP levels in ND mice. Cana pre-treatment did not affect bone strength (compression of lumbar vertebra and bending of femur mid-diaphysis) nor the ability of insulin therapy to improve bone strength. Cana and glucose group did not affect advanced glycation end-products in the organic matrix of bone, despite glycated hemoglobin A1c being much higher in the T1D mice. Cana and glucose group both independently affected crack initiation toughness such that insulin rescued the T1D-related decline of cortical bone to resist crack growth and Cana modestly added to this effect. Lastly, T1D lowered bound water in the bone matrix and insulin treatment partially reversed the decline. Thus, glycemic control prior to insulin treatment does not appear to affect the ability of insulin to prevent bone fragility in T1D mice.<\/jats:p>","DOI":"10.1007\/s00223-026-01486-x","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:12:18Z","timestamp":1769825538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Canagliflozin Pretreatment on the Efficacy of Insulin Therapy to Rescue Type 1 Diabetes-Related Bone Fragility in Male Mice"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7403-7605","authenticated-orcid":false,"given":"Jeffry S.","family":"Nyman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Clay","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasidhar","family":"Uppuganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Hennen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plaban","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Garcia","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Kalaitzoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Fowlkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"crossref","unstructured":"Lecka-Czernik B, Fowlkes JL (2015) Diabetic Bone Disease, Basic and Translational Research and Clinical Applications. Springer","DOI":"10.1007\/978-3-319-16402-1"},{"key":"1486_CR2","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2337\/dc15-0783","volume":"38","author":"DR Weber","year":"2015","unstructured":"Weber DR, Haynes K, Leonard MB et al (2015) Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using the health improvement network (THIN). Diabetes Care 38:1913\u20131920. https:\/\/doi.org\/10.2337\/dc15-0783","journal-title":"Diabetes Care"},{"key":"1486_CR3","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s00198-017-4097-x","volume":"28","author":"VN Shah","year":"2017","unstructured":"Shah VN, Harrall KK, Shah CS et al (2017) Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos Int 28:2601\u20132610. https:\/\/doi.org\/10.1007\/s00198-017-4097-x","journal-title":"Osteoporos Int"},{"key":"1486_CR4","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.2147\/dmso.s191091","volume":"12","author":"J Starup-Linde","year":"2019","unstructured":"Starup-Linde J, Hygum K, Harsl\u00f8f T, Langdahl B (2019) Type 1 diabetes and bone fragility: links and risks. Diabetes Metab Syndr Obes Targets Ther 12:2539\u20132547. https:\/\/doi.org\/10.2147\/dmso.s191091","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"1486_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2014a meta-analysis. Osteoporos Int 18:427\u2013444. https:\/\/doi.org\/10.1007\/s00198-006-0253-4","journal-title":"Osteoporos Int"},{"key":"1486_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/med.0000000000000421","volume":"25","author":"VN Shah","year":"2018","unstructured":"Shah VN, Carpenter RD, Ferguson VL, Schwartz AV (2018) Bone health in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 25:231\u2013236. https:\/\/doi.org\/10.1097\/med.0000000000000421","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1486_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/pedi.12861","volume":"20","author":"GB Fuusager","year":"2019","unstructured":"Fuusager GB, Christesen HT, Milandt N, Schou AJ (2019) Glycemic control and bone mineral density in children and adolescents with type 1 diabetes. Pediatr Diabetes 20:629\u2013636. https:\/\/doi.org\/10.1111\/pedi.12861","journal-title":"Pediatr Diabetes"},{"key":"1486_CR8","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1210\/jc.2019-00084","volume":"104","author":"SC Chen","year":"2019","unstructured":"Chen SC, Shepherd S, McMillan M et al (2019) Skeletal fragility and its clinical determinants in children with type 1 diabetes. J Clin Endocrinol Metab 104:3585\u20133594. https:\/\/doi.org\/10.1210\/jc.2019-00084","journal-title":"J Clin Endocrinol Metab"},{"key":"1486_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00592-017-0973-2","volume":"54","author":"E Maddaloni","year":"2017","unstructured":"Maddaloni E, D\u2019Eon S, Hastings S et al (2017) Bone health in subjects with type 1 diabetes for more than 50 years. Acta Diabetol 54:479\u2013488. https:\/\/doi.org\/10.1007\/s00592-017-0973-2","journal-title":"Acta Diabetol"},{"key":"1486_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bone.2019.04.017","volume":"125","author":"G Leanza","year":"2019","unstructured":"Leanza G, Maddaloni E, Pitocco D et al (2019) Risk factors for fragility fractures in type 1 diabetes. Bone 125:194\u2013199. https:\/\/doi.org\/10.1016\/j.bone.2019.04.017","journal-title":"Bone"},{"key":"1486_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178140","volume":"26","author":"G Brunetti","year":"2025","unstructured":"Brunetti G (2025) Recent updates on diabetes and bone. Int J Mol Sci 26:8140. https:\/\/doi.org\/10.3390\/ijms26178140","journal-title":"Int J Mol Sci"},{"key":"1486_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcpt.12672","volume":"120","author":"RH Bortolin","year":"2016","unstructured":"Bortolin RH, Neto FPF, Arcaro CA et al (2016) Anabolic effect of insulin therapy on the bone: osteoprotegerin and osteocalcin up-regulation in streptozotocin-induced diabetic rats. Basic Clin Pharmacol Toxicol 120:227\u2013234. https:\/\/doi.org\/10.1111\/bcpt.12672","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1486_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bonr.2017.07.001","volume":"7","author":"JS Nyman","year":"2017","unstructured":"Nyman JS, Kalaitzoglou E, Bunn RC et al (2017) Preserving and restoring bone with continuous insulin infusion therapy in a mouse model of type 1 diabetes. Bone Rep 7:1\u20138. https:\/\/doi.org\/10.1016\/j.bonr.2017.07.001","journal-title":"Bone Rep"},{"key":"1486_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bone.2016.10.026","volume":"94","author":"KM Thrailkill","year":"2017","unstructured":"Thrailkill KM, Nyman JS, Bunn RC et al (2017) The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone 94:141\u2013151. https:\/\/doi.org\/10.1016\/j.bone.2016.10.026","journal-title":"Bone"},{"key":"1486_CR15","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998270859231117091741","volume":"20","author":"PHJO Limirio","year":"2024","unstructured":"Limirio PHJO, Neto NFDO, Ven\u00e2ncio JF et al (2024) Insulin therapy on bone macroscopic, microarchitecture, and mechanical properties of tibia in diabetic rats. Curr Diabetes Rev 20:e030124225214. https:\/\/doi.org\/10.2174\/0115733998270859231117091741","journal-title":"Curr Diabetes Rev"},{"key":"1486_CR16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2106\/00004623-198971050-00014","volume":"71","author":"LR Macey","year":"1989","unstructured":"Macey LR, Kana SM, Jingushi S et al (1989) Defects of early fracture-healing in experimental diabetes. J Bone Joint Surg 71:722\u2013733","journal-title":"J Bone Joint Surg"},{"key":"1486_CR17","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.2337\/diabetes.54.10.2875","volume":"54","author":"KM Thrailkill","year":"2005","unstructured":"Thrailkill KM, Liu L, Wahl EC et al (2005) Bone formation is impaired in a model of type 1 diabetes. Diabetes 54:2875\u20132881. https:\/\/doi.org\/10.2337\/diabetes.54.10.2875","journal-title":"Diabetes"},{"key":"1486_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118593","volume":"263","author":"NP Cignachi","year":"2020","unstructured":"Cignachi NP, Ribeiro A, Machado GDB et al (2020) Bone regeneration in a mouse model of type 1 diabetes: influence of sex, vitamin D3, and insulin. Life Sci 263:118593. https:\/\/doi.org\/10.1016\/j.lfs.2020.118593","journal-title":"Life Sci"},{"key":"1486_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","volume":"82","author":"KM Thrailkill","year":"2016","unstructured":"Thrailkill KM, Bunn RC, Nyman JS et al (2016) SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice. Bone 82:101\u2013107. https:\/\/doi.org\/10.1016\/j.bone.2015.07.025","journal-title":"Bone"},{"key":"1486_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/703589","volume":"2014","author":"K Thrailkill","year":"2014","unstructured":"Thrailkill K, Bunn RC, Lumpkin C et al (2014) Loss of insulin receptor in osteoprogenitor cells impairs structural strength of bone. J Diabetes Res 2014:703589. https:\/\/doi.org\/10.1155\/2014\/703589","journal-title":"J Diabetes Res"},{"key":"1486_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"DM Nathan","year":"2014","unstructured":"Nathan DM, Group DR (2014) The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Study at 30 years: overview. Diabetes Care 37:9\u201316. https:\/\/doi.org\/10.2337\/dc13-2112","journal-title":"Diabetes Care"},{"key":"1486_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3892\/ijmm.2013.1227","volume":"31","author":"Y-F Zhao","year":"2013","unstructured":"Zhao Y-F, Zeng D-L, Xia L-G et al (2013) Osteogenic potential of bone marrow stromal cells derived from streptozotocin-induced diabetic rats. Int J Mol Med 31:614\u2013620. https:\/\/doi.org\/10.3892\/ijmm.2013.1227","journal-title":"Int J Mol Med"},{"key":"1486_CR23","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1172\/jci116060","volume":"90","author":"MJ Saad","year":"1992","unstructured":"Saad MJ, Araki E, Miralpeix M et al (1992) Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 90:1839\u20131849. https:\/\/doi.org\/10.1172\/jci116060","journal-title":"J Clin Invest"},{"key":"1486_CR24","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1074\/jbc.m116.758987","volume":"292","author":"G Xi","year":"2017","unstructured":"Xi G, Wai C, White MF, Clemmons DR (2017) Down-regulation of insulin receptor substrate 1 during hyperglycemia induces vascular smooth muscle cell dedifferentiation*. J Biol Chem 292:2009\u20132020. https:\/\/doi.org\/10.1074\/jbc.m116.758987","journal-title":"J Biol Chem"},{"key":"1486_CR25","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s00125-013-2904-2","volume":"56","author":"SJ Cleland","year":"2013","unstructured":"Cleland SJ, Fisher BM, Colhoun HM et al (2013) Insulin resistance in type 1 diabetes: what is \u2018double diabetes\u2019 and what are the risks? Diabetologia 56:1462\u20131470. https:\/\/doi.org\/10.1007\/s00125-013-2904-2","journal-title":"Diabetologia"},{"key":"1486_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.bone.2010.12.016","volume":"48","author":"JS Nyman","year":"2011","unstructured":"Nyman JS, Even JL, Jo C-H et al (2011) Increasing duration of type 1 diabetes perturbs the strength\u2013structure relationship and increases brittleness of bone. Bone 48:733\u2013740. https:\/\/doi.org\/10.1016\/j.bone.2010.12.016","journal-title":"Bone"},{"key":"1486_CR27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/med.0000000000000737","volume":"29","author":"E Kalaitzoglou","year":"2022","unstructured":"Kalaitzoglou E, Fowlkes JL, Thrailkill KM (2022) Mouse models of type 1 diabetes and their use in skeletal research. Curr Opin Endocrinol Diabetes Obes 29:318\u2013325. https:\/\/doi.org\/10.1097\/med.0000000000000737","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1486_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2014.01.021","volume":"62","author":"AJ Makowski","year":"2014","unstructured":"Makowski AJ, Uppuganti S, Wadeer SA et al (2014) The loss of activating transcription factor 4 (ATF4) reduces bone toughness and fracture toughness. Bone 62:1\u20139. https:\/\/doi.org\/10.1016\/j.bone.2014.01.021","journal-title":"Bone"},{"key":"1486_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115438","volume":"137","author":"D Harris","year":"2020","unstructured":"Harris D, Garrett K, Uppuganti S et al (2020) The BALB\/c mouse as a preclinical model of the age-related deterioration in the lumbar vertebra. Bone 137:115438. https:\/\/doi.org\/10.1016\/j.bone.2020.115438","journal-title":"Bone"},{"key":"1486_CR30","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.bone.2009.12.009","volume":"46","author":"SK Easley","year":"2010","unstructured":"Easley SK, Jekir MG, Burghardt AJ et al (2010) Contribution of the intra-specimen variations in tissue mineralization to PTH- and raloxifene-induced changes in stiffness of rat vertebrae. Bone 46:1162\u20131169. https:\/\/doi.org\/10.1016\/j.bone.2009.12.009","journal-title":"Bone"},{"key":"1486_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115126","volume":"130","author":"A Creecy","year":"2020","unstructured":"Creecy A, Uppuganti S, Girard MR et al (2020) The age-related decrease in material properties of BALB\/c mouse long bones involves alterations to the extracellular matrix. Bone 130:115126. https:\/\/doi.org\/10.1016\/j.bone.2019.115126","journal-title":"Bone"},{"key":"1486_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10443","volume":"5","author":"AM Dubrovsky","year":"2020","unstructured":"Dubrovsky AM, Nyman JS, Uppuganti S et al (2020) Bone strength\/bone mass discrepancy in glucocorticoid treated adult mice. JBMR Plus 5:e10443. https:\/\/doi.org\/10.1002\/jbm4.10443","journal-title":"JBMR Plus"},{"key":"1486_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016359","volume":"6","author":"RA Horch","year":"2011","unstructured":"Horch RA, Gochberg DF, Nyman JS, Does MD (2011) Non-invasive predictors of human cortical bone mechanical properties: T2-discriminated 1H NMR compared with high resolution X-ray. PLoS ONE 6:e16359. https:\/\/doi.org\/10.1371\/journal.pone.0016359","journal-title":"PLoS ONE"},{"key":"1486_CR34","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/jbmr.2452","volume":"30","author":"M Granke","year":"2015","unstructured":"Granke M, Makowski AJ, Uppuganti S et al (2015) Identifying novel clinical surrogates to assess human bone fracture toughness. J Bone Miner Res 30:1290\u20131300. https:\/\/doi.org\/10.1002\/jbmr.2452","journal-title":"J Bone Miner Res"},{"key":"1486_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/mrm.22459","volume":"64","author":"RA Horch","year":"2010","unstructured":"Horch RA, Nyman JS, Gochberg DF et al (2010) Characterization of 1H NMR signal in human cortical bone for magnetic resonance imaging. Magn Reson Med 64:680\u2013687. https:\/\/doi.org\/10.1002\/mrm.22459","journal-title":"Magn Reson Med"},{"key":"1486_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115625","volume":"141","author":"KM Thrailkill","year":"2020","unstructured":"Thrailkill KM, Bunn RC, Uppuganti S et al (2020) Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits. Bone 141:115625. https:\/\/doi.org\/10.1016\/j.bone.2020.115625","journal-title":"Bone"},{"key":"1486_CR37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00223-024-01252-x","volume":"115","author":"S Uppuganti","year":"2024","unstructured":"Uppuganti S, Creecy A, Fernandes D et al (2024) Bone fragility in high fat diet-induced obesity is partially independent of type 2 diabetes in mice. Calcif Tissue Int 115:298\u2013314. https:\/\/doi.org\/10.1007\/s00223-024-01252-x","journal-title":"Calcif Tissue Int"},{"key":"1486_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmbbm.2023.105731","volume":"140","author":"M Unal","year":"2023","unstructured":"Unal M, Uppuganti S, Dapaah DY et al (2023) Effect of ribose incubation on physical, chemical, and mechanical properties of human cortical bone. J Mech Behav Biomed Mater 140:105731. https:\/\/doi.org\/10.1016\/j.jmbbm.2023.105731","journal-title":"J Mech Behav Biomed Mater"},{"key":"1486_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.mcb.2017.08.008","volume":"143","author":"I Stoilov","year":"2018","unstructured":"Stoilov I, Starcher BC, Mecham RP, Broekelmann TJ (2018) Measurement of elastin, collagen, and total protein levels in tissues. Methods Cell Biol 143:133\u2013146. https:\/\/doi.org\/10.1016\/bs.mcb.2017.08.008","journal-title":"Methods Cell Biol"},{"key":"1486_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01755-x","volume":"9","author":"H Dong","year":"2024","unstructured":"Dong H, Sun Y, Nie L et al (2024) Metabolic memory: mechanisms and diseases. Signal Transduct Target Ther 9:38. https:\/\/doi.org\/10.1038\/s41392-024-01755-x","journal-title":"Signal Transduct Target Ther"},{"key":"1486_CR41","doi-asserted-by":"publisher","first-page":"274","DOI":"10.17179\/excli2022-5720","volume":"22","author":"A Ghasemi","year":"2023","unstructured":"Ghasemi A, Jeddi S (2023) Streptozotocin as a tool for induction of rat models of diabetes: a practical guide. EXCLI J 22:274\u2013294. https:\/\/doi.org\/10.17179\/excli2022-5720","journal-title":"EXCLI J"},{"key":"1486_CR42","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/nejmoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/nejmoa1611925","journal-title":"N Engl J Med"},{"key":"1486_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115254","volume":"133","author":"KM Thrailkill","year":"2020","unstructured":"Thrailkill KM, Bunn RC, Uppuganti S et al (2020) Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone. Bone 133:115254. https:\/\/doi.org\/10.1016\/j.bone.2020.115254","journal-title":"Bone"},{"key":"1486_CR44","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s11357-023-00803-8","volume":"45","author":"G Yildirim","year":"2023","unstructured":"Yildirim G, Bergamo ETP, Poudel SB et al (2023) Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice. Geroscience 45:1933\u20131951. https:\/\/doi.org\/10.1007\/s11357-023-00803-8","journal-title":"Geroscience"},{"key":"1486_CR45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2337\/db24-0955","volume":"74","author":"SB Poudel","year":"2025","unstructured":"Poudel SB, Chlebek C, Ruff RR et al (2025) Canagliflozin-induced adaptive metabolism in bone. Diabetes 74:812\u2013826. https:\/\/doi.org\/10.2337\/db24-0955","journal-title":"Diabetes"},{"key":"1486_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae128","volume":"8","author":"C Chlebek","year":"2024","unstructured":"Chlebek C, McAndrews C, Costa SN et al (2024) In nondiabetic C57BL\/6J mice, canagliflozin affects the skeleton in a sex- and age-dependent manner. JBMR Plus 8:ziae128. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae128","journal-title":"JBMR Plus"},{"key":"1486_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117301","volume":"190","author":"D Vashishth","year":"2025","unstructured":"Vashishth D, Dhaliwal R, Rubin M (2025) AGEs (Advanced Glycation End-products) in bone come of age. Bone 190:117301. https:\/\/doi.org\/10.1016\/j.bone.2024.117301","journal-title":"Bone"},{"key":"1486_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00223-023-01098-9","volume":"113","author":"MW Bolger","year":"2023","unstructured":"Bolger MW, Tekkey T, Kohn DH (2023) The contribution of perilacunar composition and mechanical properties to whole-bone mechanical outcomes in streptozotocin-induced diabetes. Calcif Tissue Int 113:229\u2013245. https:\/\/doi.org\/10.1007\/s00223-023-01098-9","journal-title":"Calcif Tissue Int"},{"key":"1486_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/jbmr\/zjae184","volume":"40","author":"SR Emerzian","year":"2024","unstructured":"Emerzian SR, Chow J, Behzad R et al (2024) Long-duration type 1 diabetes is associated with deficient cortical bone mechanical behavior and altered matrix composition in human femoral bone. J Bone Miner Res 40:87\u201399. https:\/\/doi.org\/10.1093\/jbmr\/zjae184","journal-title":"J Bone Miner Res"},{"key":"1486_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154700","volume":"11","author":"MR Rubin","year":"2016","unstructured":"Rubin MR, Paschalis EP, Poundarik A et al (2016) Advanced glycation endproducts and bone material properties in type 1 diabetic mice. PLoS ONE 11:e0154700. https:\/\/doi.org\/10.1371\/journal.pone.0154700","journal-title":"PLoS ONE"},{"key":"1486_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/jbio.201700352","volume":"11","author":"M Unal","year":"2018","unstructured":"Unal M, Uppuganti S, Leverant CJ et al (2018) Assessing glycation\u2010mediated changes in human cortical bone with raman spectroscopy. J Biophotonics 11:e201700352. https:\/\/doi.org\/10.1002\/jbio.201700352","journal-title":"J Biophotonics"},{"key":"1486_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-024-00380-2","volume":"13","author":"R Hua","year":"2025","unstructured":"Hua R, Han Y, Ni Q et al (2025) Pivotal roles of biglycan and decorin in regulating bone mass, water retention, and bone toughness. Bone Res 13:2. https:\/\/doi.org\/10.1038\/s41413-024-00380-2","journal-title":"Bone Res"},{"key":"1486_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/boneres.2015.9","volume":"3","author":"X Lai","year":"2015","unstructured":"Lai X, Price C, Modla S et al (2015) The dependences of osteocyte network on bone compartment, age, and disease. Bone Res 3:15009. https:\/\/doi.org\/10.1038\/boneres.2015.9","journal-title":"Bone Res"},{"key":"1486_CR54","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11914-016-0329-9","volume":"14","author":"E Kalaitzoglou","year":"2016","unstructured":"Kalaitzoglou E, Popescu I, Bunn RC et al (2016) Effects of type 1 diabetes on osteoblasts, osteocytes, and osteoclasts. Curr Osteoporos Rep 14:310\u2013319. https:\/\/doi.org\/10.1007\/s11914-016-0329-9","journal-title":"Curr Osteoporos Rep"},{"key":"1486_CR55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/152091599316775","volume":"2","author":"KM Thrailkill","year":"2000","unstructured":"Thrailkill KM (2000) Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther 2:69\u201380. https:\/\/doi.org\/10.1089\/152091599316775","journal-title":"Diabetes Technol Ther"},{"key":"1486_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0168-8227(94)90155-4","volume":"25","author":"PI Shishko","year":"1994","unstructured":"Shishko PI, Dreval AV, Abugova IA et al (1994) Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 25:1\u201312. https:\/\/doi.org\/10.1016\/0168-8227(94)90155-4","journal-title":"Diabetes Res Clin Pract"},{"key":"1486_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bone.2013.07.017","volume":"57","author":"JL Fowlkes","year":"2013","unstructured":"Fowlkes JL, Nyman JS, Bunn RC et al (2013) Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes. Bone 57:36\u201340. https:\/\/doi.org\/10.1016\/j.bone.2013.07.017","journal-title":"Bone"},{"key":"1486_CR58","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00223-017-0292-1","volume":"101","author":"X Wu","year":"2017","unstructured":"Wu X, Huang Z, Wang X et al (2017) Ketogenic diet compromises both cancellous and cortical bone mass in mice. Calcif Tissue Int 101:412\u2013421. https:\/\/doi.org\/10.1007\/s00223-017-0292-1","journal-title":"Calcif Tissue Int"},{"key":"1486_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.590575","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Yang Z, Xie C et al (2020) The hyperglycemia and hyperketonemia impaired bone microstructures: a pilot study in rats. Front Endocrinol 11:590575. https:\/\/doi.org\/10.3389\/fendo.2020.590575","journal-title":"Front Endocrinol"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01486-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:26:14Z","timestamp":1781630774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01486-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01486-x","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DD do not have conflicts of interest to declare. JSN holds a patent for determining mechanical properties of bone from T\n                      2\n                      -derived measures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study being reported did involve animals. Our treatment of the mice in this study followed a protocol that was approved by the local IACUC at the University of Kentucky.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights statement"}}],"article-number":"20"}}